TORONTO, Nov. 15, 2018 /CNW/ - Khiron Life Sciences Corp.
("Khiron" or the "Company") (TSXV: KHRN),
(OTCQB: KHRNF), (Frankfurt:
A2JMZC), an integrated medical cannabis company with its core
operations in Colombia, is pleased
to announce that the Company has received $14,007,000 from
the exercise of warrants of which the expiry date was accelerated
to November 14, 2018 (the
"Warrants"), as previously announced on October 25, 2018. A total of 11,672,250 warrants
were exercised, representing 96% of the Warrants, at a price of
$1.20 per Warrant. With the exercise
of the Warrants, the unaudited consolidated cash balance as at
November 15, 2018 is $24,475,978.
About Khiron Life Sciences Corp.
Khiron Life Sciences Corp. (TSXV: KRHN, OTCQB: KHRNF,
Frankfurt: A2JMZC) ("Khiron" or
the "Company") is positioned to be the dominant integrated medical
cannabis company in Latin America.
Khiron has core operations in Colombia and is fully licensed in the country
for the cultivation, production, domestic distribution, and
international export of both tetrahydrocannabinol (THC) and
cannabidiol (CBD) medical cannabis. In May
2018, Khiron listed on the TSX Venture Exchange, becoming
one of the first Colombian based medical cannabis companies to
trade on any exchange globally.
With a focused regional strategy and patient oriented
approach, the Company combines global scientific expertise,
agricultural advantages, branded product market entrance
experience and education to drive prescription and brand
loyalty to address priority medical conditions such as chronic
pain, epilepsy, depression and anxiety in the Latin American
market of over 620 million people. Khiron is led by Co-founder and
Chief Executive Officer, Alvaro
Torres, together with an experienced executive team,
and a knowledgeable Board of Directors that includes former
President of Mexico, Vicente Fox.
Further information about Khiron can be found
at www.khiron.ca and on its SEDAR profile at www.sedar.com
Forward-Looking Statements
This press release may contain certain forward-looking
information and statements ("forward-looking information") within
the meaning of applicable Canadian securities legislation, that are
not based on historical fact, including without limitation
statements containing the words "believes", "anticipates", "plans",
"intends", "will", "should", "expects", "continue", "estimate",
"forecasts" and other similar expressions. Readers are cautioned to
not place undue reliance on forward-looking information. Actual
results and developments may differ materially from those
contemplated by these statements. Khiron undertakes no obligation
to comment analyses, expectations or statements made by
third-parties in respect of Khiron, its securities, or financial or
operating results (as applicable). Although Khiron believes that
the expectations reflected in forward-looking information in this
press release are reasonable, such forward-looking information has
been based on expectations, factors and assumptions concerning
future events which may prove to be inaccurate and are subject to
numerous risks and uncertainties, certain of which are beyond
Khiron's control, including the risk factors discussed in Khiron's
Filing Statement which is available on Khiron's SEDAR profile at
www.sedar.com. The forward-looking information contained in this
press release is expressly qualified by this cautionary statement
and are made as of the date hereof. Khiron disclaims any intention
and has no obligation or responsibility, except as required by law,
to update or revise any forward-looking information, whether as a
result of new information, future events or otherwise.
Neither the TSXV nor its Regulation Services Provider (as that
term is defined in the policies of the TSXV) accepts responsibility
for the adequacy or accuracy of this press release.
View original content to download
multimedia:http://www.prnewswire.com/news-releases/khiron-life-sciences-announces-completion-of-warrant-acceleration-300751494.html
SOURCE Khiron Life Sciences Corp.